| Source | Code | Name | Case count | Share of cases (%) |
|---|---|---|---|---|
| REIMB | REIMB_KELA(202)_ICD10(M45) | Connective tissue diseases, rheumatoid arthritis and comparable disease, Ankylosing spondylitis | 1362 | |
| REIMB | REIMB_KELA(313)_ICD10(M45) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Ankylosing spondylitis | 1034 | |
| REIMB | REIMB_KELA(281)_ICD10(M45) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Ankylosing spondylitis | 996 | |
| REIMB | REIMB_KELA(313)_ICD10(M450) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Name not found | 23 | |
| REIMB | REIMB_KELA(281)_ICD10(M450) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Name not found | 21 | |
| REIMB | REIMB_KELA(3029)_ICD10(M45) | Upadacitinib, Ankylosing spondylitis | 18 | |
| REIMB | REIMB_KELA(202)_ICD10(M450) | Connective tissue diseases, rheumatoid arthritis and comparable disease, Name not found | 14 | |
| REIMB | REIMB_KELA(202)_ICD9(M45) | Connective tissue diseases, rheumatoid arthritis and comparable disease, Name not found | 8 |